EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks
All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.
You may also be interested in...
The European Food Safety Authority is evaluating new reproductive and developmental toxicity data published since it paused CBD novel food applications last year due to safety concerns, according to food law consultancy, Legal Foods.
Italy reclassifies natural CBD as a narcotic drug. The decision may see challenges from companies marketing in Italy natural CBD supplements registered in other European countries, given that the European Court of Justice (CJEU) overturned a similar position taken by France in 2020.
Market's direction depends on different influences, according to witnesses testifying at recent House hearing looking at FDA’s position on using hemp ingredients in food and dietary supplements. Rising costs and plummeting prices hit marketers as acreage for hemp and amount harvested shrink.